BJH - volume 13, issue 4, june 2022
S. Bonte PhD, T. Kerre MD, PhD
Acute myeloid leukaemia (AML) has a dismal outcome, as demonstrated by a 5-year overall survival rate of only 26%. Although a complete remission can be achieved in approximately 50% of the patients with classical chemotherapy, the chances of relapse are high. Current treatment options for relapsed or refractory AML only offer a bridge to allogeneic haematopoietic stem cell transplantation since no other curative option exists. In primary refractory patients, and patients at high risk for relapse, harnessing the power of the immune system with immunotherapy might provide a new treatment option. In this dissertation, we approached AML immunotherapy from two sides: the optimisation of TCR-based immunotherapy for AML, and of the identification of patients eligible for this type of treatment.
(BELG J HEMATOL 2022;13(4):165–7)
Read moreBJH - volume 11, issue Abstract Book BHS, february 2020
S. Bonte PhD, S. Van Gassen , A. Couckuyt , V. Janda , I. Moors MD, dr. A. Delie MD, S. Kennes MD, J. Philippé MD, PhD, Y. Saeys , T. Kerre MD, PhD
BJH - 2018, issue Abstract Book BHS, february 2018
S. Bonte PhD, S. Snauwaert MD, PhD, G. Goetgeluk , B. Vandekerckhove MD, PhD, T. Kerre MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
S. Bonte PhD, S. Snauwaert MD, PhD, G. Goetgeluk , B. Vandekerckhove MD, PhD, T. Kerre MD, PhD
BJH - volume 7, issue Abstract Book BHS, january 2016
S. Bonte PhD, S. Snauwaert MD, PhD, M. Heemskerk , B. Vandekerckhove MD, PhD, T. Kerre MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
S. Bonte PhD, S. Snauwaert MD, PhD, G. Goetgeluk , M.H.M. Heemskerk MD, PhD, H. Stauss , R. Stripecke , B. Vandekerckhove MD, PhD, T. Kerre MD, PhD
BJH - volume 5, issue Abstract Book BHS, january 2014
P. Vlummens MD, S. Bonte PhD, V. Van Hende MD, T. Kerre MD, PhD
Top
